17 Participants Needed

LM-302 for Solid Cancer

Recruiting at 16 trial locations
JZ
EH
TP
BS
Fl
Overseen ByFirst line of the email MUST contain the NCT# and Site #.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing a new drug called LM-302 in patients with advanced cancers that have a specific protein called CLDN18.2. The drug aims to attach to this protein on cancer cells to help stop their growth. Another drug targeting the same protein has been developed and tested in previous studies.

Who Is on the Research Team?

BS

Bristol-Myers Squibb

Principal Investigator

Bristol-Myers Squibb

Are You a Good Fit for This Trial?

Adults (18+) with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. Participants must be informed about the trial and willing to sign consent, have a life expectancy of at least 3 months, an ECOG performance status of 0-1, and appropriate organ function. CLDN18.2 positive status may be required for certain phases.

Inclusion Criteria

You are expected to live for at least three more months.
You understand what the study is about, the way it will be conducted, the potential side effects, and you agree to participate by signing an informed consent form.
You have been diagnosed with an advanced solid tumor that has come back or did not respond to standard treatments. You cannot tolerate these treatments or there are no other available options. Examples of these tumors include stomach, esophagus, pancreas, liver, colon cancers, and ovarian cancer.
See 14 more

Exclusion Criteria

You received anti-cancer treatment within 3 weeks before starting LM-302.
You have severe pain related to your tumor that is not being managed well.
You have a build-up of fluid around your heart or in your lungs or abdomen that is not under control and requires frequent removal.
See 21 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

4 weeks
1 visit (in-person)

Treatment

Participants receive dose escalation of LM-302 every 3 weeks

Up to 1 year
Every 3 weeks (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks
1 visit (in-person)

Long-term follow-up

Participants are monitored for long-term safety and effectiveness

Up to 2 years

What Are the Treatments Tested in This Trial?

Interventions

  • LM-302
Trial Overview LM-302 is being tested in this Phase I trial on patients with CLDN18.2-positive advanced solid tumors. The study involves increasing doses to find safe levels (dose escalation) followed by further testing at these levels (dose expansion).
How Is the Trial Designed?
6Treatment groups
Experimental Treatment
Group I: LM302 Dose Escalation Level 6, 2.8mg/kgExperimental Treatment1 Intervention
Group II: LM302 Dose Escalation Level 5, 2.4mg/kgExperimental Treatment1 Intervention
Group III: LM302 Dose Escalation Level 4, 1.6mg/kgExperimental Treatment1 Intervention
Group IV: LM302 Dose Escalation Level 3, 0.8 mg/kgExperimental Treatment1 Intervention
Group V: LM302 Dose Escalation Level 2, 0.4 mg/kgExperimental Treatment1 Intervention
Group VI: LM302 Dose Escalation Level 1, 0.2 mg/kilogram(kg),Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

LaNova Medicines Limited

Lead Sponsor

Trials
13
Recruited
1,400+
Founded
2019
Headquarters
Shanghai, China
Known For
Cancer Therapies
Top Products
LM-299, LM-302, LM-108

Turning Point Therapeutics, Inc.

Lead Sponsor

Trials
10
Recruited
790+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security